Sunday Funday! If you follow me on the Instagrams, you saw the above post about Eli Lilly. Oh, how things have changed inside Eli Lilly since the prohibition of cannabis began in 1937. So without further ado, below is a link to Eli Lilly’s SEC filing from March 2018 for your review.

Many believe big Pharma is behind some of the lag in federal policy change; and while I do not disagree, we must remember how lobbying works. Lobbying is only successful when an entity or person is willing to accept funds in exchange for a vote. In 2018, Kaiser Health News published the article Key Democrat Leaders Have Pocketed Millions From Pharma, which stated, “In the past decade, members of Congress from both parties have received about $81 million from 68 pharma Political Action Committees run by employees of companies that make drugs.” As long as federal government officials are allowed to accept lobbying dollars then the path to reform remains in favor of the highest bidder, not American voters.

Today, Americans have grown skeptical of big corporations’, big governments’, and big lobbyists’ intentions. According to the Pew Research Center, “Three-quarters of Americans say that their fellow citizens’ trust in the federal government has been shrinking”. Based on the above-provided documentation, it would appear neither the pharmaceutical industry nor the federal government has any intentions of reigning in greedy behaviors or caring for people they serve.

Cannabis policy reform should focus solely on the health and wellness of all Americans, and not the government’s or pharma’s pocketbook. Please register to vote in 2020 and help move the issue of cannabis policy reform forward.